Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Galveston, Texas • Seattle, Washington

Conditions: Tuberculosis
Interventions: DAR-901, BCG, Sterile saline; Biological
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Rotavirus Infections
Interventions: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo; Biological · Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV I Infection
Interventions: Vacc-4x, Sterile water; Drug
Lead sponsor: Bionor Immuno AS; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Miami, Florida + 1 more

Conditions: Needle Phobia
Interventions: Lidocaine patch 4%; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Peanut Allergy
Interventions: ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more

Conditions: Acute Migraine
Interventions: ZP-Zolmitriptan, Placebo; Drug
Lead sponsor: Zosano Pharma Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 36
States / cities: Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more

Conditions: Pain
Interventions: IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D); Drug · Other
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tuberculosis Infection
Interventions: BCG (Tokyo 172) vaccine, Placebo; Biological · Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Decatur, Georgia + 4 more

Conditions: Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor
Interventions: Dendritic cell immunotherapy; Drug
Lead sponsor: Northwest Biotherapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Castro Valley, California + 56 more

Conditions: Ovarian Cancer, Ovarian Neoplasms
Interventions: Vigil, Placebo; Biological · Other
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 26
States / cities: Mobile, Alabama • Irvine, California • San Francisco, California + 22 more

Conditions: Cluster Headache
Interventions: C213 Microneedle System, Placebo; Drug
Lead sponsor: Zosano Pharma Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Santa Monica, California + 9 more

Conditions: Alzheimer Disease
Interventions: AV-1959D, Placebo; Biological
Lead sponsor: Institute for Molecular Medicine; Other
Eligibility: 60 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Phoenix, Arizona • Newport Beach, California • Tampa, Florida + 3 more

Conditions: Smallpox
Interventions: MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lichen Sclerosus of Vulva
Interventions: Platelet Rich Plasma, Placebo; Biological · Drug
Lead sponsor: Center for Vulvovaginal Disorders; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions: PVX-108, Placebo; Biological
Lead sponsor: Aravax Pty Ltd; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more

Conditions: Chronic Cutaneous Ulcer, Sickle Cell Disease
Interventions: Deferoxamine Product, Placebo; Drug · Other
Lead sponsor: TauTona Group; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 1 more

Conditions: Pregnancy
Interventions: Local Anesthesia, Placebo Group; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy
Interventions: MitoQ, Placebo, MitoTempo, Tempol, L-NAME, SNP - Sodium Nitroprusside; Dietary Supplement · Drug
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Lucanix™, Placebo Comparator; Biological · Other
Lead sponsor: NovaRx Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more

Conditions: Glioblastoma
Interventions: Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epithelial Ovarian Cancer
Interventions: Cvac, Placebo; Biological
Lead sponsor: Prima BioMed Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Gastroenteritis Escherichia Coli, Immunisation
Interventions: Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

Phase I Trial of DAR-901

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

Lidocaine Patch vs Intradermal Lidocaine for Epidural Needle Insertion Pain

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

A Trial of Vigil for Participants With Ovarian Cancer

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

Study of AV-1959D, an Amyloid Beta Vaccine

ACAM 3000 MVA at Harvard Medical School

Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

Local Anesthesia and Pain Perception During an Amniocentesis

Effects of an Antioxidant Supplement on Blood Vessel Health

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area